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Abstract: Ricin exhibits well characterized ribotoxic actions that lead to the inhibition of 
protein  synthesis  and  the  phosphorylation  of  stress  activated  protein  kinases  (SAPKs). 
Proinflammatory  effects  of  ricin  are  thought  to  be  caused  by  upregulation  of  genes 
encoding  proinflammatory  transcripts  as  a  result  of  the  activation  of  c-Jun  N-terminal 
kinase (JNK) and p38 MAPK. We reported previously that macrophages and interleukin-1 
(IL-1 signaling are required for murine host immune responses to ricin delivered to the 
lungs.  Here  we  report  that  ricin-mediated  IL-1release  from  bone-marrow  derived 
macrophages  is  dependent  on  the  NALP3  inflammasome,  a  scaffolding  complex  that 
mediates  pro-IL-1  cleavage  to  active  IL-1  by  caspase-1.  Release  of  IL-1  from 
macrophages was suppressed by the reactive oxygen species (ROS) scavenger N-acetyl 
cysteine  (NAC)  and  high  extracellular  K
+,  which  are  two  agents  known  to  inhibit 
NALP3/cryopyrin/CIAS1  inflammasome  formation.  By  employing  inhibitors  of  p38 
MAPK and JNK, we demonstrated that ricin-mediated release of IL-1 was enhanced, 
rather than suppressed, by inhibition of SAPK phosphorylation. In contrast, proteasomal 
inhibitors  bortezomib  and  MG-132  completely  suppressed  ricin-induced  IL-1  release 
from macrophages. These data suggest that ricin-mediated translational inhibition itself, by 
fostering  the  disappearance  of  labile  protein(s)  that  normally  suppress  inflammasome 
formation,  may  constitute  the  mechanism  underlying  IL-1-dependent  inflammatory 
signaling by ricin. 
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1. Introduction  
Ricin is a potent inhibitor of protein synthesis that triggers a robust proinflammatory response when 
administered to mice and non-human primates [1]. Mounting evidence points to the macrophage as the 
specific  cell  type  responsible  for  ricin’s  lethal  effects  in  vivo  [2–4].  In  primary  bone-marrow  
derived- (BMDM) and alveolar macrophages, exposure to ricin causes the phosphorylation of stress 
activated protein kinases (SAPKs) p38 MAPK and JNK, and triggers the transcriptional upregulation 
of genes encoding proinflammatory cytokines and chemokines [3,5]. In vivo, depletion of macrophages 
prior to delivery of ricin to the pulmonary system of mice results in diminished inflammatory signs, 
including reduced neutrophilia and pulmonary edema [6].  
IL-1β  signaling  is  an  essential  component  of  ricin-mediated  inflammation.  Mice  deficient  in  
IL-1α/β or IL-1R display enhanced survival as well as decreased neutrophilia and pulmonary edema 
compared to wild-type mice after exposure to ricin [6]. Ricin’s ability to induce neutrophilia can be 
restored  in  IL-1α/β-deficient  animals  by  the  co-administration  of  exogenous  IL-1β  with  ricin. 
Furthermore,  the  IL-1  receptor  antagonist  anakinra  (Kineret®)  provides  protection  against  ricin-
mediated inflammatory effects in wild-type mice, confirming a central role of IL-1 in ricin toxicity. 
IL-1β secretion by macrophages is a tightly regulated process involving at least two distinct signals 
[7,8]. Macrophages first require priming by Toll-like receptor (TLR) ligands (such as LPS) or by 
cytokines  (such  as  TNFα  or  IL-1β  itself)  in  order  to  induce  the  expression  of  pro-IL-1β.  The  
pro-form of IL-1β is inactive and requires cleavage by the cysteine protease caspase-1 for maturation 
and  secretion  [9].  Molecular  platforms  called  inflammasomes  stimulate  caspase-1 activity  and  are 
necessary for IL-1β processing [10,11]. One of the best-characterized inflammasome complexes is the 
NALP3  (or  NLRP3/cyropyrin)  inflammasome.  This  multiprotein  complex  includes  the  NOD-like 
receptor  (NLR)  family  member  NALP3,  the  cysteine  protease  caspase-1,  and  the  adaptor  protein 
apoptosis-associated  specklike  protein  (ASC),  which  facilitates  interaction  of  caspase-1  with  
NALP3 [12,13]. 
NLRs such as NALP3 are intracellular sensors of pathogen-associated molecular patterns (PAMPs) 
and danger-associated molecular patterns (DAMPs) [14]. Unlike AIM2, an NLR family member that 
senses dsRNA through direct ligand binding, NALP3 is thought to be a more general sensor of cellular 
stress through a mechanism that is not fully understood [15]. NALP3 inflammasomes are activated by 
a  diverse  array  of  agents  including  exogenous  danger  signals  such  as  bacterial  RNA,  Candida 
albicans,  and  influenza  [16–18],  environmental  stressors  such  as  silica  and  asbestos  [19–21],  and 
endogenous danger signals such as ATP, uric acid and amyloid β [22–24].  
While a singular mechanism cannot yet explain the activation of the NALP3 inflammasome by its 
wide array of activators, two events that may be common to all known activators are the generation of 
reactive oxygen species (ROS) and the efflux of potassium [20,21,25,26]. ROS generation by NALP3 
agonists is believed to indirectly cause activation of the inflammasome via the ROS-sensitive TXNIP 
protein [27]. Studies show that inhibitors of ROS can reduce the amount of mature IL-1β released by Toxins 2010, 2                   
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cells after stimulation with ATP, asbestos, and silica [21,28]. However, work on human monocytes 
lacking  functional  NADPH  oxidase  did  not  show  a  connection  between  ROS  and  NALP3 
inflammasome activation [29], suggesting that ROS generation may not always be required. In regards 
to  the  role  of  potassium,  it  is  thought  that  the  intracellular  assembly  of  NALP3  inflammasomes 
requires a low potassium environment [30]. Activation of caspase-1 is suppressed by normal levels of 
intracellular  potassium  [31],  and  two  laboratories  have  shown  that  the  efflux  of  K
+  can  directly 
promote the oligomerization of ASC and its association with caspase-1 [26,32].  
Here  we  report  that  ricin  toxin  is  an  activator  of  the  NALP3  inflammasome.  We  found  that  
ricin-mediated IL-1β release from primary bone marrow-derived macrophages not only required the 
expression of NALP3, ASC and caspase-1, but also was inhibited by co-treatment of cells with the 
ROS scavenger N-acetyl-cysteine (NAC) or high extracellular potassium. In addition, we found that 
the  activation  of  JNK  and  p38  MAPK  by  ricin  was  not  inhibited  by  either  NAC  or  elevated 
extracellular potassium, suggesting that ricin mediates IL-1 release from cells in a manner that is 
independent of its ability to activate kinases.    
Proinflammatory consequences of ricin are thought to be initiated by phosphorylation of ZAK, a 
MAP3K that transduces the signal through downstream kinases p38 MAPK and JNK and leads to 
proinflammatory gene expression [33]. We found that treatment of cells with inhibitors reported to 
bind to ZAK [34,35] (Nilotinib and Sorafenib) led to inhibition of p38 and JNK activity but failed to 
block ricin-mediated release of IL-1β from macrophages. We hypothesized that inhibition of protein 
synthesis might be the event that triggers activation of the NALP3 inflammasome by contributing to 
the disappearance of important repressor proteins from the cell. By employing proteasome inhibitors to 
suppress proteasomal degradation of cellular proteins, we found that ricin-induced IL-1 release from 
macrophages required active proteasomes. Together these data describe a novel mechanism governing 
ricin-mediated inflammatory signaling. 
2. Materials and Methods  
2.1. Reagents and Antibodies 
Ricin was purchased from Vector Laboratories (Burlingame, CA). LPS (L-2630), N-acetyl cysteine 
(NAC), and bovine-pancreas insulin (I6634) were purchased from Sigma-Aldrich (St. Louis, MO). 
Trichloroacetic  acid  (TCA)  was  purchased  from  Fisher  Scientific  (Pittsburgh,  PA).  Nilotinib, 
Sorafenib  and  Bortezomib  were  obtained  from  LC  Laboratories  (Woburn,  MA).  MG-132,  the  
p38-specific  inhibitor  SB203580,  and  the  JNK  inhibitor  SP600125  were  purchased  from  EMD 
Biosciences  (Gibbstown,  NJ).  The  mouse  IL-1  enzyme-linked  immunosorbent  assay  (ELISA)  
Ready-Set-Go was purchased from eBioscience (San Diego, CA). Anti-IL-1 was purchased from 
Abcam (Cambridge, MA), anti-ASC was purchased from Enzo Life Sciences (Lausen, Switzerland), 
and anti-p38, anti-cryopyrin (H-66)/NALP3, and anti-caspase-1 (M-20) were purchased from Santa 
Cruz Biotechnology (Santa Cruz, CA). Anti-phospho-SAPK/JNK (9251S), anti-phospho-p38 MAPK 
(9211S),  anti-phospho-MAPKAP-2  (3041S)  were  purchased  from  Cell  Signaling  Technologies 
(Danvers, MA).   Toxins 2010, 2                   
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2.2. Animals and Animal Procedures 
All animal procedures were performed according to protocols approved by the Institutional Animal 
Care and Use Committee at Oregon Health and Science University, Portland, Oregon. C57BL/6J and 
Caspase-1  deficient  mice  were  purchased  from  The  Jackson  Laboratory  (Bar  Harbor,  ME).  
ASC-deficient  and  NALP3-deficient  mice  were  kindly  provided  by  V.  Dixit  (Genentech,  San 
Francisco,  CA).  Male  mice,  8–10  weeks  of  age,  were  used  throughout  the  experiments.  Before 
experimental  procedures,  mice  were  anesthetized  intraperitoneally  with  80  mg/kg  of  ketamine  and  
10 mg/kg of xylazine.  
2.3. Isolation and Treatment of Bone Marrow-Derived Macrophages 
Bone  marrow-derived  macrophages  were  prepared  from  C57BL/6J,  ASC
−/−,  Caspase-1
−/−,  and 
NALP3
−/− mice. Marrow was flushed from femurs and tibias with PBS and cultured in -Minimum 
Essential Medium (α-MEM, Cellgro, Herndon, VA), supplied with 10% Fetal Bovine Serum (FBS, 
Cellgro, Herndon, VA), 50 μg/mL gentamicin, and 100 ng/mL recombinant mouse Colony Stimulating 
Factor 1 (CSF-1, R&D Systems, Minneapolis, MN) for 72 h on non-tissue culture treated 10-cm petri 
dishes. Cells were passaged and cultured for an additional 72h. Cells from one confluent 10-cm dish 
were plated into one 6-well tissue culture plate (Sarstedt, Newton, NC) for an additional 24 h before 
experiments. Cells were serum-deprived in -MEM for 30 min followed by treatment with 50 ng/mL 
LPS for 4 h. Cells were rinsed with fresh media and exposed to 0.01 µ g/mL ricin in serum-free media 
for  an  additional  4  h  prior  to  harvesting.  In  experiments  involving  co-treatments  with  ricin  plus  
N-acetyl-cysteine (30 mM), high potassium (130 mM), Nilotinib (1 µ M), Sorafenib (1 µ M), SB203580 
(10  µ M),  SP600125  (20  µ M),  bortezomib  (0.5  M)  or  MG-132  (10  M),  cells  were  exposed  to 
indicated  concentrations  of  inhibitors.  In  experiments  involving  high  potassium,  potassium  was 
substituted for sodium in the medium in order to maintain equivalent ion concentrations.  
2.4. Immunoblotting and IL-1 ELISA 
BMDM cells were lysed in 2X ESB lysis buffer in preparation for immunoblotting. Equal volumes 
of the cell lysates were separated on a 10% denaturing polyacrylamide gel in the presence of sodium 
dodecyl sulfate and were transferred onto polyvinylidene difluoride membranes according to standard 
laboratory procedures. Proteins from BMDM media supernatants were precipitated using TCA and run 
on 13% gels. Briefly, samples were incubated at 4 ° C overnight with 200 µ g insulin carrier and 400 µ L 
ice-cold  100%  TCA  prior  to  centrifugation  at  12,000  rpm  for  5  min.  Pellets  were  air  dried  and 
resuspended in 2X ESB lysis buffer followed by separation on a 13% denaturing polyacrylamide gel. 
Membranes  were  incubated  with  the  indicated  antibodies  and  the  corresponding  horseradish 
peroxidase-conjugated  secondary  antibodies;  signals  were  detected  using  enhanced 
chemiluminescence. Media supernatants were analyzed in triplicate using IL-1 ELISA (eBioscience) 
according to the manufacturer’s protocol. 
2.5. Statistical Analysis 
Individual  groups  were  compared  using  unpaired  t  test  analysis  and  were  interpreted  in  a  
two-tailed manner. Toxins 2010, 2                   
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3. Results 
3.1. Ricin Stimulates IL-1 Release from Wild-Type Bone Marrow Derived Macrophages 
Studies in vivo and in vitro have demonstrated that macrophages constitute primary targets of ricin 
[3,5,6]. Wild-type (WT) alveolar and bone-marrow derived macrophages respond similarly to ricin in 
that they both display phosphorylation of p38 MAPK and JNK in dose-dependent manner inversely 
proportional to the ricin-mediated decrease in levels of protein translation [3]. In order to determine if 
macrophages release IL-1 in response to these same doses, wild-type BMDM were first primed for  
4 h with LPS (50 ng/mL) to induce pro-IL-1 expression, after which cells were rinsed and exposed to 
varying concentrations of ricin for 4 h (Figure 1). Whole cell lysates (WCL) and media supernatants 
were  subjected  to  immunoblotting  and  ELISA for detection  of IL-1. Ricin alone  did  not  induce 
expression of pro-IL-1. Priming with LPS led to an increase in levels of 37 kDa pro-IL-1 in cell 
lysates, and subsequent exposure to ricin led to the appearance of processed 17 kDa IL-1in the 
media. Processed IL-1 was detected in media supernatants for all doses tested. We chose to use the 
lowest dose, 0.01 µ g/mL, for all subsequent experiments. The B subunit of ricin is responsible for 
binding to cell surfaces, but lacks the N-glycosidase activity of the A subunit that is responsible for 
depurination of 28S rRNA. Exposure of LPS-primed macrophages to purified ricin B subunit failed to 
elicit appearance of p17 IL-1 in the culture medium (data not shown), suggesting that interactions 
between ricin holotoxin and surface molecules do not elicit signals that elicit processing of pro-IL-1. 
Figure 1. Ricin stimulates IL-1 release from WT BMDM. Secreted IL-1 was measured 
by ELISA analysis of media supernatants collected from LPS-primed WT BMDM after 4 h 
ricin exposure. Bars represent the mean ±  s.d. of triplicate wells. Results are representative 
of three individual experiments. Media supernatants were also precipitated and subjected to 
immunoblot analysis for detection of IL-1 p17. WCLs were subjected to immunoblot 
analysis for detection of pro-IL-1 and p38 MAPK as a loading control. 
  Toxins 2010, 2                   
 
 
1505 
3.2. Ricin-Mediated Release of IL-1 Requires NALP3, ASC and Caspase-1 
Secretion of processed IL-1 from cells requires discrete events, including the accumulation of  
pro-IL-1 through a priming step and the assembly of the inflammasome, a multiprotein scaffolding 
complex  that  both  activates  caspase-1  and  brings  caspase-1  into  close  proximity  with  pro-IL-1 
[7,10]).  The  best-studied  inflammasome  complex  is  the  NALP3  inflammasome,  in  which  NALP3 
associates with caspase-1 through the adaptor protein ASC [12,13]. The NALP3 inflammasome has 
been shown to mediate cellular responses to several danger-associated molecular patterns: exogenous 
danger signals such as silica and asbestos [19,21], and endogenous danger signals such as ATP and 
uric acid [22,23,36]. To determine if macrophages sense and respond to ricin through the NALP3 
inflammasome, we compared the ricin-mediated responses of WT cells to responses of cells deficient 
in NALP3, ASC, or caspase-1 (Figure 2). BMDM from each mouse strain were primed with LPS for  
4  h  prior  to  ricin  treatment.  After  4  h  exposure  to  ricin,  cells  were  harvested  and  processed  for 
immunoblotting  (Figure  2A)  to  examine  expression  levels  of  inflammasome  components  and  
pro-IL-1. Media supernatants were subjected to detection of IL-1 by immunoblotting and ELISA  
(Figure 2B). Although pro-IL-1 was similarly induced in the LPS-primed cells of each strain, the 
processing of pro-IL-1 to active IL-1 was significantly decreased in cells deficient in either NALP3, 
ASC or caspase-1. These results suggest that the NALP3 inflammasome is required for ricin-mediated 
IL-1 processing and release from BMDM. 
Figure 2. Ricin-mediated release of IL-1 requires NALP3, ASC, and caspase-1. Primed 
and  unprimed  WT,  NALP3
−/−,  casp-1
−/−,  and  ASC
−/−  BMDM  were  treated  with  
±  0.01 µ g/mL ricin or vehicle alone (co) for 4 h. WCLs were subjected to immunoblotting 
for NALP3 inflammasome components, pro-IL-1 and p38 MAPK. Media supernatants 
were  either  precipitated  for  immunoblot  analysis  (A)  or  subjected  to  ELISA  for 
measurement of secreted IL-1 (B). Bars represent the mean ±  s.d. of triplicate wells.  
 Toxins 2010, 2                   
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3.3. Elevated Extracellular K
+ and N-Acetyl-Cysteine Prevent Ricin-Mediated Secretion of IL-1 
If NALP3 mediates the release of IL-1 from macrophages exposed to ricin, then agents shown to 
inhibit the activity of the NALP3 inflammasome should block the appearance of IL-1 in the medium 
after  exposure  to  ricin.  To  address  this  question  we  employed  two  inhibitors  of  the  NALP3 
inflammasome:  increased  extracellular  potassium  (K
+)  and  the  ROS  scavenger,  N-acetyl-cysteine. 
High extracellular K
+ blocks IL-1 release caused by a variety of danger signals that activate NALP3 
including asbestos, silica, and ATP [37]. In vitro studies of inflammasome activation suggest that 
NALP3  inflammasome  assembly  requires  a  low  K
+  intracellular  environment  [26].  In  addition, 
activation of NALP3 is reportedly blocked by ROS inhibitors like NAC through a mechanism that is 
not well understood [25]. Wild-type BMDM were primed with LPS for 4 h, after which cells were  
co-treated with increased extracellular potassium or NAC and ricin. Four hours later, cells and media 
supernatants were harvested and processed for immunoblot analysis and ELISA. Media collected from 
cells co-treated with ricin and either NAC or elevated extracellular K
+ contained 50% and 75% less  
IL-1 respectively, than cells treated with ricin alone. Untreated cells and cell exposed to NAC or 
elevated K
+ expressed equivalent amounts of pro-IL-1β (Figure 3). Interestingly, exposure of cells to 
NAC or elevated K
+ did not diminish ricin-mediated phosphorylation of p38 MAPK or the p38 MAPK 
target, MAPKAP2. Furthermore, NAC by itself led to phosphorylation of p38 MAPK and MAPKAP2 
while  diminishing  the  release  of  IL-1  from  ricin-treated  cells,  suggesting  that  ricin-mediated 
inflammasome activation and SAPK phosphorylation are not necessarily linked.  
Figure 3. Elevated extracellular K
+ and NAC prevent ricin-mediated secretion of IL-1 
from WT BMDM. Primed WT cells were treated ±  0.01 µ g/mL ricin in combination with 
either NAC or K
+ for 4 h. A) WCLs were subjected to immunoblotting for phospho-p38 
MAPK,  phospho-MAPKAP2,  pro-IL-1  and  p38  MAPK  as  a  loading  control.  Media 
supernatants were either precipitated for immunoblotting (A) or subjected to ELISA for 
determination of secreted IL-1 (B). Bars represent the mean ±  s.d. of triplicate wells  
(**: p < 0.01).  
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3.4.  Ricin-Mediated  Phosphorylation  of  p38  MAPK  and  JNK  Is Not  Required for  Ricin-Mediated  
IL-1 Secretion 
If ricin-mediated phosphorylation of SAPKs is an upstream event leading to NALP3 activation, 
then blocking the phosphorylation of these kinases should prevent the appearance of IL-1 in the 
media of ricin-treated cells. To address this question we employed SB203580, an inhibitor of p38 
MAPK,  and  SP600125,  an  inhibitor  of  JNK.  We  also  employed  two  inhibitors  (Nilotinib  and 
Sorafenib) that have been reported to have very high affinity for the ATP-binding site of ZAK [34,35], 
the upstream MAP3K that is phosphorylated by ricin and other ribotoxic stressors [33]. LPS-primed 
cells were treated with SB203580 (SB), SP600125 (SP), Sorafenib, Nilotinib or ricin, alone and in 
combination for 4 h, at which time cell lysates and media supernatants were collected (Figure 4). 
Phosphorylated  SAPKs  and  pro-IL-1  levels  were  examined  in  cell  lysates  by  immunoblotting. 
Processed  IL-1  from  media  supernatants  was  detected  using  both  immunoblotting  and  ELISA. 
Inhibitors  exhibited  varying  degrees  of  effectiveness  in  suppressing  SAPKs.  JNK  activation  was 
decreased marginally by SP and significantly by Sorafenib; p38 MAPK activation was diminished 
significantly by Nilotinib and Sorafenib; and the activation of MAPKAP2, a target of p38 MAPK, was 
significantly decreased by SB, Nilotinib, and Sorafenib. Surprisingly, SB stimulated IL-1 release 
from macrophages on its own, and cells co-treated with kinase inhibitors and ricin secreted similar or 
greater amounts of IL-1 as cells treated only with ricin, despite diminished levels of phosphorylated 
p38  MAPK  and  JNK  in  these  cells.  These  data  suggest  that  SAPK  activation  by  ricin  is  not  a 
requirement for the release of IL-1 from ricin-treated cells and that suppression of ricin-mediated 
ZAK activation did not reduce ricin-induced activation of the NALP3 inflammasome. 
3.5. Proteasome Inhibitors Block Ricin-Mediated Release of IL-1 from WT BMDM 
Importantly, the dose of ricin used in this study (0.01 µ g/mL) elicits a 50% inhibition of protein 
synthesis by 3 h in addition to its effects on SAPKs and the release of IL-1 [3]. We hypothesized that 
inhibition  of  protein  synthesis  per  se  could  lead  to  activation  of  NALP3  by  contributing  to  the 
disappearance  of  labile  proteins  which  may  regulate  the  availability  of  NALP3  to  participate  in 
formation of the inflammasome. In such case, proteasomal activity may be required for ricin-induced 
activation of NALP3 and release of IL-1 from macrophages. To test this hypothesis, we employed the 
specific  and  potent  proteasome  inhibitors  bortezomib  and  MG-132.  Although  cells  exposed  to 
bortezomib or MG-132 expressed similar levels of pro-IL-1 to cells exposed only to LPS or ricin, 
cells exposed to bortezomib or MG-132 exhibited complete suppression of ricin-mediated secretion of 
IL-1(Figure 5). These data are consistent with the notion that translational inhibition itself may be a 
mechanism by which ricin triggers IL-1 dependent inflammatory signaling. Toxins 2010, 2                   
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Figure  4.  Ricin-mediated  phosphorylation  of  p38  MAPK and  JNK is  not  required  for  
ricin-mediated  IL-1  secretion.  Primed  WT  cells  were  treated  ±   0.01  µ g/mL  ricin  in 
combination with either SB203580, SP600125, SB + SP, Nilotinib or Sorafenib for 4 h.  
(A)  WCLs  were  subjected  to  immunoblotting  for  phospho-JNK,  phospho-p38  MAPK, 
phospho-MAPKAP2, pro-IL-1 and p38 MAPK as a loading control. Media supernatants 
were either precipitated and subjected to immunoblotting (A) or analyzed for IL-1 by 
ELISA; (B) Bars represent the mean ±  s.d. of triplicate wells. 
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Figure 5. Proteasome inhibitors block ricin-mediated release of IL-1 from WT BMDM. 
Primed cells were treated ± 0.01 µ g/mL ricin and either bortezomib, MG-132, or vehicle 
alone (co) for 4 h. Secreted IL-1 was measured by ELISA from media supernatants. Bars 
represent  the  mean  ±   s.d.  of  triplicate  wells  (**:  p  <  0.01).  WCLs  were  subjected  to 
immunoblotting for detection of pro-IL-1and p38 MAPK as a loading control. 
 
4. Discussion 
Previously  we  demonstrated  that,  in  addition  to  inhibiting  protein  synthesis,  ricin  triggers  the 
phosphorylation of JNK and p38 MAPK. Activation of these kinases is required for ricin-mediated 
expression of mRNAs encoding inflammatory cytokines and chemokines [38,39]. Furthermore, we 
showed that ricin administration to the lungs results in a neutrophilic inflammation  in vivo that is 
dependent on IL-1 and on the presence of macrophages [6]. Experiments in BMDM and alveolar 
macrophages  demonstrated  that  macrophages  constitute  primary  targets  for  ricin,  and  are  a  likely 
source  of  ricin-induced  production  of  IL-1  [3,5,6].  However,  the  mechanism  of  ricin-mediated 
processing and release of IL-1 was unclear.  
Here  we  report  that  ricin  triggers  IL-1  release  from  macrophages  in  a  NALP3-,  ASC-  and  
caspase-1-dependent  manner,  and  that  ricin-mediated  IL-1  release,  but  not  ricin-mediated  SAPK 
phosphorylation, may be blocked by treatment of cells with high extracellular potassium or the ROS 
scavenger,  NAC.  In  addition,  we  found  that  IL-1  release  is  not  dependent  upon  p38  or  JNK 
activation, since inhibitors that target the p38 MAPK and JNK pathways failed to block IL-1 release 
and indeed, even enhanced IL-1 secretion from primed cells. Furthermore, treatment of macrophages 
with proteasome inhibitors in combination with ricin demonstrated that ricin-mediated IL-1 release 
was  dependent  upon  the  proteasomal  degradation  of  cellular  proteins.  Taken  together,  these  data 
suggest  a  novel  mechanism  for  ricin-mediated  inflammatory  signaling,  and  helps  to  explain  why 
inhibitors of IL-1 signaling are capable of diminishing ricin’s inflammatory effects. 
The  major  finding  of  this  study  is  that  macrophages  require  components  of  the  NALP3 
inflammasome (NALP3, ASC, and caspase-1) in order to process and release active IL-1 after ricin Toxins 2010, 2                   
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exposure (Figure 2). NALP3 is a Nod-like receptor protein containing a pyrin-domain (PYD) through 
which it interacts with the PYD-containing adaptor protein, ASC, upon oligomerization [40]. ASC 
binds caspase-1 through its caspase-1 recruitment domain (CARD) and stimulates its activity, so that 
the  IL-1  precursor  may  be  cleaved  into  its  active  form,  p17  IL-1,  and  secreted  by  the  cell  in 
response to danger signals. Although primed WT BMDM expressed similar levels of pro-IL-1 as the 
NALP3-, ASC-, and caspase-1-deficient BMDM (Figure 2a), the mutant BMDM all failed to release 
IL-1 into the medium after ricin treatment. These results suggest that the NALP3 inflammasome is 
required for ricin-mediated processing of IL-1.  
As  a  sensor  of  a  myriad  of  microbial  and  non-microbial  danger  signals  and  the  culprit  of  
pyrin-associated autoinflammatory diseases caused by mutations in the nlrp3 gene [41,42], the NALP3 
inflammasome is well-studied but still poorly understood. Unlike TLRs, which bind directly to their 
ligands [43], studies suggest that NALP3 may instead sense an intermediate molecule produced by its 
activators. While the list of activators grows longer each year, the mechanism through which dissimilar 
signals trigger NALP3 activity remains unclear.  
Although insufficient to activate the NALP3 inflammasome on their own, potassium efflux and 
ROS production are common events that occur during NALP3 activation by all known activators [25]. 
Evidence  suggests  that  ASC  oligomerization  and  caspase-1  activation  require  a  low  potassium 
environment  [26,32].  Indeed,  high  extracellular  potassium  applied  to  macrophages  to  prevent  
ricin-mediated potassium efflux resulted in significantly diminished IL-1 secretion in ricin-treated 
cells  (Figure  3),  despite  expressing  normal  levels  of  pro-IL-1  after  priming.  Furthermore,  the  
ROS-scavenger NAC was able to reduce IL-1 release by 50% in ricin-treated BMDM (Figure 3), 
consistent  with  the  notion  that  intracellular  ROS  may  be  permissive  for  activation  of  the  
NALP3 inflammasome. 
In  order  to  determine  whether  SAPK  phosphorylation  was  required  for  ricin-mediated 
inflammasome activation, we employed inhibitors known to have high affinity for ZAK (Nilotinib and 
Sorafenib)  as  well  as  inhibitors  specific  to  the  p38  MAPK  (SB203580)  and  JNK  (SP600125). 
Surprisingly,  we  found  that  inhibiting  ricin-mediated  SAPK  activation  enhanced,  rather  than 
suppressed,  IL-1  release  from  primed  macrophages  (Figure  4).  These  data  suggest  that  SAPK 
phosphorylation  by  ricin  may  suppress  the  NALP3  inflammasome  rather  than  contribute  to  its 
activation. The partial suppression of ZAK by kinase inhibitors failed to diminish NALP3 activation, 
suggesting  that  NALP3  activation  by  ricin  occurs  by  a  mechanism  that  does  not  involve  ZAK. 
However,  the  possibility  that  ZAK  contributes  to  ricin-mediated  activation  of  the  NALP3 
inflammasome cannot be excluded at this time. 
Another possibility is that ricin induces activity of the NALP3 inflammasome through the inhibition 
of  cellular  protein  translation  per  se  by  depleting  cells  of  proteins  that  suppress  formation  of 
inflammasome complexes under normal conditions. The existence of a family of small proteins that 
have emerged as important inflammasome
 regulators lends merit to this idea. These proteins contain 
either  pyrin-only  domains  (POPs)  or  CARD-only  domains  (COPs)  and  act  as  endogenous  
dominant-negative modulators of inflammasome activity [44]. One might imagine a scenario in which 
their  disappearance  from  the  cell  could  trigger  activation  of  the  inflammasome  as  a  result  of  
ricin-induced inhibition of protein synthesis combined with normal protein turnover.  Toxins 2010, 2                   
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To  explore  this  possibility,  we  treated  WT  BMDM  with  two  different  proteasome  inhibitors, 
bortezomib  and  MG-132,  and  examined  ricin-mediated  IL-1  release  under  conditions  in  which 
proteasomal degradation of cellular proteins was blocked. Our experiments demonstrated that both 
bortezomib  and  MG-132  signficantly  reduced  IL-1  secretion  from  WT  cells  exposed  to  ricin, 
supporting the hypothesis that ricin-mediated translational inhibition itself may lead to activation of 
the NALP3 inflammasome by fostering the disappearance of labile protein(s). It would be interesting 
to examine whether other inhibitors of protein translation similarly activate inflammatory signaling 
through NALP3.  
Since  host  immune  responses  triggered  by  toxins  are  nonproductive  and  often  deleterious, 
investigation into mechanisms underlying inflammatory signaling by toxins is warranted so that we 
might better understand and manage toxin-induced pathologies. 
5. Conclusions 
When  added  to  LPS-primed  murine  bone  marrow-derived  macrophages,  ricin  induces  the 
processing  of  pro-IL-1  to  IL-1,  which  is  secreted  into  the  culture  medium.  The  conversion  of 
pro-IL-1 to IL-1 is prevented in macrophages deficient in NALP3, ASC, or caspase-1, suggesting 
that ricin induces the formation of the NALP3 inflammasome. The mechanism by which ricin mediates 
the  secretion  of  IL-1  through  formation  of  the  NALP3  inflammasome  does  not  involve  the 
stimulation  of  JNK  and  p38  MAPK  or  activation  of  ZAK.  Proteasome  inhibitors  suppress  
ricin-mediated inflammasome activation, suggesting that the turnover of labile suppressor protein(s) 
may be responsible for restraining the formation of the NALP3 inflammasome. 
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